Literature DB >> 7859798

Communicating a drug alert. A case study on acitretin in The Netherlands.

M C Sturkenboom1, L T de Jong-van den Berg, M C Cornel, B H Stricker, H Wesseling.   

Abstract

In October 1990, a recall procedure was initiated for the teratogenic drug acitretin, and the recommended post-therapy contraception period after acitretin therapy was extended from 2 months to 2 years due to the possibility of its conversion to the lipophilic compound etretinate. The aim of the present study was to evaluate the communication procedures and their effects as a drug alert from the health authorities, the pharmaceutical company and professional associations of health professionals to the population at risk. A model was used to evaluate communication between three hierarchical levels. Data were obtained via semi-structured interviews and structured questionnaires. Communication procedures were evaluated according to channel characteristics and by analysis of their contents. The effect was measured as whether the drug dispensers identified acitretin users, contacted physicians, and whether physicians communicated in person with the population at risk. The penetration of direct mail from the health authorities and from the pharmaceutical company ranged from 97-98% and 65-94% at Level 2 (health professionals). The population at risk was informed via personal communication with health professionals, and/or the mass media. Of the women at risk, 19% were contacted by a dermatologist, 30% by their GP, and 39% by the pharmacist. 35% was never informed by any health professional. The Dutch health care system is adequately equipped for effective communication between health authorities, pharmaceutical industry and health professionals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859798     DOI: 10.1007/bf00194961

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Thirty years after thalidomide: still plenty to do.

Authors:  K H Kimbel
Journal:  Int J Risk Saf Med       Date:  1993

2.  Etretinate. Persistent serum levels after long-term therapy.

Authors:  J J DiGiovanna; L A Zech; M E Ruddel; G Gantt; G L Peck
Journal:  Arch Dermatol       Date:  1989-02

3.  A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.

Authors:  K Kragballe; C T Jansén; J M Geiger; J R Bjerke; E S Falk; L Gip; N Hjorth; J Lauharanta; N J Mork; T Reunala
Journal:  Acta Derm Venereol       Date:  1989       Impact factor: 4.437

4.  Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.

Authors:  S B Soumerai; J Avorn; S Gortmaker; S Hawley
Journal:  Am J Public Health       Date:  1987-12       Impact factor: 9.308

5.  Ad hoc tracing of a cohort of patients exposed to acitretine (Neotigason) on a nation-wide scale.

Authors:  B H Stricker; M Barendregt; R M Herings; L T de Jong-van den Berg; M C Cornel; P A de Smet
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  5 in total
  4 in total

Review 1.  Communication of medical product risk: how effective is effective enough?

Authors:  Stephen A Goldman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration.

Authors:  Hélène Théophile; Ghada Miremont-Salamé; Philip Robinson; Nicholas Moore; Bernard Bégaud; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2011-05-20       Impact factor: 2.953

3.  Information about drugs in family magazines.

Authors:  A M van Trigt; L T de Jong-van den Berg; M Pasman; F M Haaijer-Ruskamp; J Willems; T F Tromp
Journal:  Pharm World Sci       Date:  1995-03-24

Review 4.  Changing prescribing in the light of tolerability concerns: how is this best achieved?

Authors:  C S de Vries; C A Duggan; T F Tromp; L T de Jong-van den Berg
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.228

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.